Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a
medical aesthetics company focused on enhancing lives by advancing
the art of plastic surgery, announced the appointment of Alexander
W. Casdin to the Company’s Board of Directors, effective June 15,
2023.
“On the heels of no less than 3 new product
approvals in the United States in the past 12 months, and with
continued strong topline performance and a near-term path to
profitability, we are delighted to welcome Alex to the Sientra
Board of Directors,” said Caro Van Hove, Executive Chair of
Sientra. “With Kevin O'Boyle retiring from the Board after nearly a
decade of exceptional Board leadership and financial governance,
Alex's deep strategic and operational expertise across the life
sciences industry is an excellent match and of great value to
Sientra's continued double-digit growth plan and commitment to a
strong financial position."
Mr. Casdin has deep experience as a healthcare
operating executive, investor and advisor with more than twenty
years of experience. Mr. Casdin is currently the Chief Operating
Officer of Epirium Bio, a biotechnology company with a small
molecule platform of therapies targeted to improve muscle function.
Mr. Casdin also served as Epirium’s Chief Financial Officer prior
to his current role. Before joining Epirium, Mr. Casdin was founder
and Chief Executive & Chief Investment Officer (CEO-CIO) of
Reneo Capital Management LP, a healthcare investment fund. In
addition, he served in roles as Chief Financial Officer of Sophiris
Bio, Inc; Vice President of Finance at Amylin Pharmaceuticals; and
Portfolio Manager for Health Care at Pequot capital. He also led
Casdin Advisors, LLC, a strategic advisory firm providing services
in the life science industry.
Mr. Casdin has served on the Board of Directors
of multiple successful healthcare companies, and helped steward
those companies to successful IPOs and or acquisitions, including
Ignyta, Inc. and Dusa Pharmaceuticals, Inc, which were acquired by
Roche and Sun Pharmaceuticals, respectively. He currently serves as
a Board member and Audit Chair of Erasca, Inc. In addition, Mr.
Casdin is currently a Board member and Treasurer of the Conquer
Cancer Foundation of the American Society of Clinical Oncology
(ASCO) and serves on the Advisory Board for the Hassenfeld
Children’s Center at NYU Langone Medical Center.
“I am very pleased to be joining the Board of Sientra at this
important time,” said Mr. Casdin. “The Company’s leadership in
breast reconstruction, as demonstrated by its continued market
share gains and its impressive disruptive new technologies, coupled
with its commitment to disciplined cash management, creates an
exciting opportunity to deliver meaningful shareholder value. I
look forward to collaborating with the Board and senior management
team to support Sientra in its mission to be the most innovative
and trusted partner to plastic surgeons and patients.”
About Sientra
Headquartered in Irvine, California, Sientra is a medical
aesthetics company exclusively focused on plastic surgery. The
Company mission is to offer proprietary innovations and
unparalleled partnerships that radically advance how plastic
surgeons think, work and care for their patients. Sientra has
developed a broad portfolio of products with technologically
differentiated characteristics, supported by independent laboratory
testing and strong clinical trial outcomes. The Company’s product
portfolio includes its Sientra round and shaped breast implants,
the first fifth-generation breast implants approved by the FDA for
sale in the United States, its ground-breaking AlloX2® breast
tissue expander with patented dual-port and integral drain
technology, the Viality™ with AuraClens™ enhanced viability fat
transfer system, the SimpliDerm® Human Acellular Dermal
Matrix, and BIOCORNEUM® the #1 performing, preferred and
recommended scar gel of plastic surgeons (*).
Sientra uses its investor relations website to publish important
information about the Company, including information that may be
deemed material to investors. Financial and other information about
Sientra is routinely posted and is accessible on the Company’s
investor relations website at www.sientra.com.
(*) Data on file
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, based on management’s current assumptions and expectations
of future events and trends, which affect or may affect the
Company’s business, strategy, operations or financial performance,
and actual results may differ materially from those expressed or
implied in such statements due to numerous risks and uncertainties.
Forward-looking statements are made only as of the date of this
release. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’
‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’
‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of
those terms, and similar expressions that convey uncertainty of
future events or outcomes are intended to identify estimates,
projections, and other forward-looking statements. Forward-looking
statements may include information concerning the Company’s
possible or assumed future results of operations, including
descriptions of the Company’s revenues, profitability, outlook, and
overall business strategy, the Company’s ability and timing to
successfully integrate new products into its existing operations,
the clinical performance of the Company’s products, the reception
of plastic surgeons to the Company’s products, and the Company’s
ability to capture additional market share and customer accounts in
the plastic surgery market. Such statements are subject to risks
and uncertainties, including the positive reaction from plastic
surgeons and their patients to the Company’s products, the ability
to meet consumer demand, including any potential supply issues
resulting from the COVID-19 pandemic or the war in Ukraine, the
growth of the plastic surgery market and breast procedures, and the
ability of the Company to execute on its commercial, marketing,
research and development and regulatory plans. Additional factors
that could cause actual results to differ materially from those
contemplated in this press release can be found in the Risk Factors
section of Sientra’s public filings with the Securities and
Exchange Commission. All statements other than statements of
historical fact are forward-looking statements. The words
‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’
‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’
‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar
expressions that convey uncertainty of future events or outcomes
are intended to identify estimates, projections, and other
forward-looking statements. You are cautioned not to place undue
reliance on these forward-looking statements, and such estimates,
projections, and other forward-looking statements speak only as of
the date they were made, and, except to the extent required by law,
the Company undertakes no obligation to update or review any
estimate, projection or forward-looking statement. Actual results
may differ from those set forth in this press release due to the
risks and uncertainties inherent in the Company’s business.
Investor Relations ContactAman R. Patel,
CFAaman.patel@westwicke.com
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Oct 2023 to Oct 2024